Michele L Donato MD MBA FACP CPE

Oncology•Hackensack, NJ

Hematologic Oncology

Chief, Stem Cell Transplantation and Cellular Therapy Program

Join to View Full Profile

92 2nd StreetHackensack, NJ 07601

Summary

Dr. Michele Donato is an oncologist in Hackensack, NJ and is affiliated with Hackensack Meridian Health Hackensack University Medical Center. She received her medical degree from McGill University Faculty of Medicine and has been in practice 25 years. She also speaks multiple languages, including French. She specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and hodgkin's lymphoma.

Education & Training

University of Massachusetts MBA, 2018 - 2022
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1995 - 1997
McGill University Faculty of MedicineClass of 1992

Certifications & Licensure

DC State Medical License 2004 - 2026
NY State Medical License 2012 - 2026
NJ State Medical License 2005 - 2025
TX State Medical License 1997 - 2007
PA State Medical License 1996 - 1998
American Board of Internal Medicine Medical Oncology
American Association of Physician LeadersCPE

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer Start of enrollment: 1995 Sep 01
Completed
Phase 1, Phase 2
Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia Start of enrollment: 2010 Apr 12
Terminated
Phase 3
Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma Start of enrollment: 2010 Apr 08
Completed
Phase 3
PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation Start of enrollment: 2010 Jun 16
Terminated
Phase 3
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older Start of enrollment: 2010 Jun 24
Terminated
Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Start of enrollment: 2010 Jun 09
Completed
Phase 2
In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus Start of enrollment: 2011 Aug 01
Terminated
Phase 1, Phase 2
A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes Start of enrollment: 2017 Jun 27
COMPLETED
PHASE1
Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence Start of enrollment: 2016 Jun 07
Terminated
Phase 1, Phase 2
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant Start of enrollment: 2019 Mar 08
TERMINATED
PHASE1
RAPA-501 Therapy for ALS Start of enrollment: 2024 Dec 01
RECRUITING
PHASE2, PHASE3
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection Start of enrollment: 2020 Apr 09
Terminated
Phase 2
Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection Start of enrollment: 2020 Nov 06
Terminated
Phase 2
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma Start of enrollment: 2020 Jun 30
ACTIVE_NOT_RECRUITING
PHASE3
Expanded Access to Convalescent Plasma for Treatment of COVID-19
No longer available
Join now to see all

Publications & Presentations

PubMed

cfDNA Chimerism and Somatic Mutation Testing in Early Prediction of Relapse After Allogeneic Stem Cell Transplantation for Myeloid Malignancies.
Scott D Rowley, Maher Albitar, Melissa F Baker, Alaa Ali, Sukhdeep Kaur
Cancers. 2025-02-13
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma.
Binod Dhakal, Parameswaran Hari, Saurabh Chhabra, Aniko Szabo, Lawrence G Lum
Journal for Immunotherapy of Cancer. 2025-01-28
Impact of Allogeneic Stem Cell Transplant on Safety and Outcomes of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Patients with Multiple Myeloma (MM).
Ayrton Bangolo, Behzad Amoozgar, Lili Zhang, Vignesh K Nagesh, Imranjot Sekhon
Journal of Clinical Medicine. 2024-10-18

Abstracts/Posters

Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients
Michele L. Donato, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)
Michele L. Donato, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Evomela¬ Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation
Michele L. Donato, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Pilot Study of Telmisartan (Micardis) for Prevention of Acute Graft Vs. Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: Interim Analysis
Michele L. Donato, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Elotuzumab As Post-Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Myeloma
Michele L. Donato, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC)
Michele L. Donato, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treat...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplan...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Bone Marrow Transplant Program Opens at Jersey Shore University Medical CenterAugust 19th, 2022
2022 N.J. Top Cancer Doctors Deliver Quality and Compassionate Care, Close to HomeJune 16th, 2022
Philippines Again Extends COVID-19 Travel Ban on 10 Countries, Including UAE and OmanAugust 13th, 2021
Join now to see all